Related Experiment Videos
[Sentinel lymph node biopsy in malignant melanoma--an update]
Lutz Kretschmer1, Hans Peter Bertsch, Johannes Meller
1Abteilung Dermatologie und Venerologie, Georg-August-Universität Göttingen, Germany. lkre@med.uni-goettingen.de
Summary
Sentinel lymph node biopsy (SLNB) is a sensitive melanoma staging tool. While its role as standard care is debated, early nodal disease excision after SLNB may improve survival for high-risk melanoma patients.
Area of Science:
- Oncology
- Surgical Pathology
Background:
- Sentinel lymph node biopsy (SLNB) has been used for 10 years in malignant melanoma management.
- Its sensitivity is high, but false-negative results require consideration.
- The role of SLNB as standard care for high-risk patients remains under discussion.
Purpose of the Study:
- To evaluate the current status and impact of sentinel lymph node biopsy in malignant melanoma management.
- To assess the prognostic significance of SLNB findings.
- To review the therapeutic consequences and uncertainties following SLNB.
Main Methods:
- Review of prospective multicentre trials and retrospective studies on sentinel lymph node biopsy in melanoma.
- Analysis of the prognostic value of SLNB pathologic status.
- Examination of survival data related to early versus delayed lymph node dissection.
Main Results:
- Three prospective trials did not show a survival benefit from elective lymph node dissection.
- A retrospective study indicated improved overall survival with early nodal excision after positive SLNB.
- SLNB pathologic status is the most significant prognostic factor for melanoma recurrence and survival.
Conclusions:
- Sentinel lymph node biopsy is a crucial prognostic tool in melanoma management.
- Early excision of nodal metastases identified by SLNB may enhance survival.
- Lack of universally accepted adjuvant therapies and unclear benefits of complete lymph node dissection post-SLNB present ongoing challenges.